NORMAL SITUATION

PHARMES

Export PDF
Financial year 2023 · closed on 31/12/2023
Net result
-84,3 k €
-183.9% YoY
Gross margin
-15,6 k €
-106.6% YoY
Equity
26,1 k €
-76.3% YoY
Workforce
0,0 ETP

Company — Normal situation.

What does PHARMES do?

PHARMES is a company registered in Belgium.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0773.651.907
Legal form
Private limited company
Contributed capital
100 000,00 €
Latest accounts
31/12/2023
Average workforce
0,0 ETP
Signals
Healthy social debts
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 2 financial years

20232022
Income statement
Gross margin-15,6 k €237,4 k €
EBITDA-73 k €122 k €
Operating result-83,2 k €108,6 k €
Net result-84,3 k €100,4 k €
Balance sheet
Equity26,1 k €110,4 k €
Total assets152,7 k €440,4 k €
Cash40,9 k €204,5 k €
Debts126,6 k €303 k €
Other
Workforce0,0 ETP0,0 ETP
Governance

Board of directors

Seen on filing of 31/12/2023 · 2 active · 1 ended

Active mandates

Essenzie

Director · since 06 janvier 2023 · 0679.835.683

Represented by Sven MARTENS

Active
SvM

Director · since 07 septembre 2021 · 0884.431.053

Represented by Sven MARTENS

Active

Ended mandates

PHARMES

Director · since 07 septembre 2021 · 0773.651.907

Represented by Sven MARTENS

Ended
Annual accounts

Full financial information

20232022
Type of accountAbridged modelAbridged model
Start of the financial year01/01/202308/09/2021
Closing of the financial year31/12/202331/12/2022
Length of the financial year12 months16 months
Filing date19/06/202428/07/2023
General meeting21/05/202416/06/2023
Currency of the financial yearEUREUR
NBB quality labelSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

2 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202321/05/202419/06/2024DutchPDF
Abridged model31/12/202216/06/202328/07/2023DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2023 · 2 active · 1 ended

Active mandates

Essenzie

Director · since 06 janvier 2023 · 0679.835.683

Represented by Sven MARTENS

Active
SvM

Director · since 07 septembre 2021 · 0884.431.053

Represented by Sven MARTENS

Active

Ended mandates

PHARMES

Director · since 07 septembre 2021 · 0773.651.907

Represented by Sven MARTENS

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Dissolution23/09/2024
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2023
    Annual accounts 2023-84,3 k €↓
  2. 2022
    Annual accounts 2022100,4 k €